论文部分内容阅读
达比加群作为新型口服抗凝药，近年已被众多指南推荐为防治血栓栓塞性疾病或心房颤动且具有脑卒中风险的一线药物。相对于华法林，达比加群在临床疗效、患者依从性及安全性等方面具有更多优势。现就达比加群的临床疗效及安全性等方面的新近报道进行综述。“,”The new oral anticoagulant dabigatran has been recommended as a first-line drug by many guidelines for the prevention and treatment of thromboembolic disorders or atrial fibrillation with high risk of stroke .Compared with warfarin , dabigatran has more advantages in clinical curative effect , and patient compliance and safety .The newly published efficacy and safety of dabigatran has been reviewed in this article.